-
公开(公告)号：KR1020090064705A
公开(公告)日：2009-06-22
申请号：KR1020070132002
申请日：2007-12-17
Applicant: 강화군
IPC: A61K31/7034 , A61K31/35 , A61K36/31 , A61P13/12
CPC classification number: A61K31/7034 , A61K36/31
Abstract: A pharmaceutical composition for preventing and treating disease of nephrotoxicity caused by anticancer drug is provided to reduce the nephrotoxicity and enhance anticancer activity. A pharmaceutical composition for preventing and treating diseases of nephrotoxicity caused by an anticancer drug comprises a zingerone-4-O-beta-D-glucopyranoside as an active ingredient. The zingerone-4-O-beta-D-glucopyranoside is isolated from a Brassica rapa. The zingerone-4-O-beta-D-glucopyranoside is contained in a ratio of 0.01-98 weight%. An anticancer adjuvant having inhibition activity to nephrotoxicity caused by anticancer drug comprises the zingerone-4-O-beta-D-glucopyranoside as an active ingredient.
Abstract translation: 提供了用于预防和治疗由抗癌药物引起的肾毒性疾病的药物组合物，以减少肾毒性并增强抗癌活性。 用于预防和治疗由抗癌药引起的肾毒性疾病的药物组合物包含作为有效成分的姜油酮-4-O-β-D-吡喃葡萄糖苷。 从芸苔属油菜籽中分离出了姜黄酮-4-O-β-D-吡喃葡萄糖苷。 姜黄酮-4-O-β-D-吡喃葡萄糖苷的含量为0.01-98重量％。 由抗癌药物引起的对肾毒性具有抑制活性的抗癌佐剂，以姜黄酮-4-O-β-D-吡喃葡萄糖苷为活性成分。
-
公开(公告)号：KR1020090064702A
公开(公告)日：2009-06-22
申请号：KR1020070131999
申请日：2007-12-17
Applicant: 강화군
IPC: A61K31/4045 , A61K31/404 , A61K36/31 , A61P9/02
CPC classification number: A61K31/404 , A61K36/31
Abstract: A pharmaceutical composition containing Brassica rapa extracts is provided to prevent and treat kidney toxicity diseases by cisplatin and cardiac circulation disease by LDL oxidation. A pharmaceutical composition for preventing and treating kidney toxicity diseases which is caused by an anticancer drug comprises 0.01-98 weight% of 4-methoxyindole-3-acetonitrile as an active ingredient. The 4-methoxyindole-3-acetonitrile is isolated from a Brassica rapa. An anticancer adjuvant having suppression activity to kidney toxicity comprises the 4-methoxyindole-3-acetonitrile. A pharmaceutical composition for preventing and treating cardiac circulation diseases comprises the 4-methoxyindole-3-acetonitrile as an active ingredient. The cardiac circulation diseases are hyperlipidemia, cerebral artery, coronary heart disease, arteriosclerosis or myocardial infarction.
Abstract translation: 提供含有芸苔属提取物的药物组合物，通过LDL氧化预防和治疗顺铂和心脏循环疾病的肾脏毒性疾病。 用于预防和治疗由抗癌药物引起的肾毒性疾病的药物组合物包含0.01-98重量％的4-甲氧基吲哚-3-乙腈作为活性成分。 从芸苔属油菜中分离4-甲氧基吲哚-3-乙腈。 对肾毒性具有抑制活性的抗癌佐剂包括4-甲氧基吲哚-3-乙腈。 用于预防和治疗心脏循环疾病的药物组合物包含4-甲氧基吲哚-3-乙腈作为活性成分。 心脏循环疾病是高脂血症，脑动脉，冠心病，动脉硬化或心肌梗死。
-
公开(公告)号：KR1020120069964A
公开(公告)日：2012-06-29
申请号：KR1020100131319
申请日：2010-12-21
Applicant: 강화군
IPC: A61K31/4045 , A61K31/404 , A61K36/31 , A61P3/04
CPC classification number: A61K31/404 , A23L33/105 , A61K31/275 , A61K36/31 , A61K2236/53 , C07D209/14 , Y10S514/909
Abstract: PURPOSE: An anti-obesity composition containing 1-methoxy indole-3-acetonitrile or 4-methoxy indole-3-acetonitrile is provided to ensure excellent and safe anti-obesity function. CONSTITUTION: An anti-obesity composition contains 1-methoxy indole-3-acetonitrile or 4-methoxy indole-3-acetonitrile as an active ingredient. The active ingredient is isolated from Brassica rapa. A method for preparing 1-methoxy indole-3-acetonitrile comprises: a step of extracting Brassica rapa. with methanol; a step of extracting the methanol extract with ethyl acetate/H_2O and isolating an H_2O layer with n-BuOH/H_2O; a step of decompressing each layer to obtain ethyl acetate fraction, n-butanol fraction, and water fraction; a step of performing silicagel column chromatography of the ethyl acetate fraction; and a step of purifying 7th fraction(BE7 fraction) with octadesyl silicagel.
Abstract translation: 目的：提供含有1-甲氧基吲哚-3-乙腈或4-甲氧基吲哚-3-乙腈的抗肥胖组合物，以确保优异安全的抗肥胖功能。 构成：抗肥胖组合物含有1-甲氧基吲哚-3-乙腈或4-甲氧基吲哚-3-乙腈作为活性成分。 活性成分从芸苔属中分离出来。 一种制备1-甲氧基吲哚-3-乙腈的方法包括：提取芥菜的步骤。 用甲醇; 用乙酸乙酯/ H_2O萃取甲醇萃取液，用正丁醇/ H_2O分离H_2O层; 减压各层以获得乙酸乙酯部分，正丁醇馏分和水馏分的步骤; 进行乙酸乙酯级分的硅胶柱色谱的步骤; 以及用八甲基硅胶纯化第七级分（BE7级分）的步骤。
-
14.发明授权순무 추출물로부터 분리된 4―메톡시인돌―3―아세토니트릴을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물 有权包含从芸苔属油菜中分离出的用于预防和治疗炎性疾病的4-甲氧基吲哚-3-乙腈的组合物
公开(公告)号：KR101072288B1
公开(公告)日：2011-10-11
申请号：KR1020090053426
申请日：2009-06-16
Applicant: 강화군
IPC: A61K31/404 , A61K36/31 , A61P29/00 , A23L1/30
Abstract: 본발명은순무(L.) 추출물로부터분리된화합물을유효성분으로함유하는조성물에관한것으로, 상세하게는순무추출물로부터분리된화합물 4-메톡시인돌-3-아세토니트릴(4-methoxyindole-3-acetonitrile, arvelexin)이생체내 실험() 및시험관내 실험()에서염증으로유도된부종과호중구의유입, PGE생성및 COX-2 발현, NO 생성및 iNOS 발현, 염증성사이토카인의생성및 mRNA 발현, NF-&kgr;B-DNA 결합및 NF-&kgr;B 전사활성, NF-&kgr;B의핵 전좌와 I&kgr;Bα의인산화및 IKKα/&bgr;의활성과 MAPKs의인산화에대한억제효과를확인함으로써, 상기조성물을염증성질환의예방및 치료용약학조성물또는건강기능식품으로유용하게이용할수 있다.
-
15.发明公开순무 추출물로부터 분리된 4―메톡시인돌―3―아세토니트릴을 유효성분으로 함유하는 염증성 질환의 예방 및 치료용 조성물 有权包含从BRASSICA RAPA分离的4-甲氧基-3-三氟乙酸的预防和治疗炎症疾病的组合物
公开(公告)号：KR1020100077114A
公开(公告)日：2010-07-07
申请号：KR1020090053426
申请日：2009-06-16
Applicant: 강화군
IPC: A61K31/404 , A61K36/31 , A61P29/00 , A23L1/30
CPC classification number: A61K31/404 , A61K36/31 , Y10S514/825 , Y10S514/886
Abstract: PURPOSE: A composition containing a compound isolated from Brassica campestris L. ssp. Rapa extract is provided to use in a pharmaceutical composition or health food for preventing and treating inflammatory disorders. CONSTITUTION: A pharmaceutical composition for preventing and treating inflammatory disorder contains 4-methoxyindole-3-acetonitrile(arvelexin) compound which is isolated form Brassica campestris L. ssp. Rapa extract or pharmaceutically acceptable salt thereof as an active ingredient. Inflammatory disorders are atopic dermatitis, psoriasis, rheumatoid arthritis, spondylitis, urethritis, cystitis, nephritis, allergosis, or dermatoneurology. A health food for preventing and treating inflammatory disorders contains 4-methoxyindole-3-acetonitrile compound and pharmaceutically acceptable salt as an active ingredient. The health food is used in the form of powder, granule, tablet, capsule or beverage.
Abstract translation: 目的：一种组合物，其中含有从芸苔属（Brassica campestris L. ssp。 提供Rapa提取物用于药物组合物或保健食品中以预防和治疗炎症性疾病。 构成：用于预防和治疗炎性疾病的药物组合物含有4-甲氧基吲哚-3-乙腈（arvelexin）化合物，其分离自芥菜油菜。 Rapa提取物或其药学上可接受的盐作为活性成分。 炎症性疾病是特应性皮炎，牛皮癣，类风湿性关节炎，脊椎炎，尿道炎，膀胱炎，肾炎，过敏原或皮肤病学。 用于预防和治疗炎性疾病的保健食品含有4-甲氧基吲哚-3-乙腈化合物和药学上可接受的盐作为活性成分。 保健食品以粉末，颗粒，片剂，胶囊或饮料的形式使用。
-
Patent Agency Ranking
公开(公告)号：KR100949012B1
公开(公告)日：2010-03-23
申请号：KR1020070131992
申请日：2007-12-17
Applicant: 강화군
IPC: A61K31/352 , A61K36/282 , A61P35/00
Abstract: 본 발명은 사자발쑥 추출물을 포함하는 약학 조성물에 관한 것으로, 특히 사자발쑥 추출물 중 유파폴린(Eupafolin)을 유효성분으로 포함하여 암 질환 뿐 아니라 심장순환계 질환의 예방 및 치료에 효과적인 약학 조성물에 관한 것이다.
유파폴린, 사자발쑥, 난소암, 폐암, 뇌종양, 동맥경화, 고지혈증-
公开(公告)号：KR100926413B1
公开(公告)日：2009-11-12
申请号：KR1020070132002
申请日：2007-12-17
Applicant: 강화군
IPC: A61K31/7034 , A61K31/35 , A61K36/31 , A61P13/12
Abstract: 본 발명은 항암제에 의해 유발되는 신장 독성 질환 예방 및 치료용 약학 조성물에 관한 것으로, 특히 순무로부터 추출한 진저론-4-
O -
β -
D -글루코피라노사이드(Zingerone-4-
O -
β -
D -glucopyranoside)를 유효성분으로 포함함으로써 기존 항암제로 사용되는 시스플라틴(cisplatin)과 같이 투여할 경우 시스플라틴의 부작용인 신장 독성을 감소시키면서 항암 효능을 증진시킬 수 있는 항암제에 의해 유발되는 신장 독성 질환 예방 및 치료용 약학 조성물에 관한 것이다.
진저론-글루코피라노사이드, 시스플라틴, 신장 독성, 항암제-
公开(公告)号：KR1020090086506A
公开(公告)日：2009-08-13
申请号：KR1020090069668
申请日：2009-07-29
Applicant: 강화군
IPC: C07D307/77 , A61K31/352 , A61K36/282 , A61P35/00
Abstract: A pharmaceutical composition containing Artemisia princeps PAMPANINI extract or sesquiterpene compound isolated from the extract is provided to have strong cytotoxicity such as suppression of cancer cell proliferation or induction of apoptosis. A pharmaceutical composition for treating cancer or heart circulatory diseases comprises Artemisia princeps PAMPANINI extract or sesquiterpene compound of the chemical formula 1 isolated from the extract. The sesquiterpene compound of the chemical formula 1 is 3-(2-methyl-butyryloxy)-costu-1(10),4(5)-dien-12,6-olide. A method for producing the sesquiterpene compound of the chemical formula 1 comprises: a step of dipping dried Artemisia princeps in low alcohol of C1-C4 for 24 hours; and a step of filtering, compressing and fractioning.
Abstract translation: 提供含有从提取物中分离的青蒿提取物或倍半萜烯化合物的药物组合物以具有强的细胞毒性，例如抑制癌细胞增殖或诱导细胞凋亡。 用于治疗癌症或心脏循环系统疾病的药物组合物包括从提取物中分离的化学式1的青蒿提取物或倍半萜烯化合物。 化学式1的倍半萜化合物是3-（2-甲基 - 丁酰氧基） - 硬脂酸-1（10），4（5） - 二 - 12,6-二醇。 制备化学式1的倍半萜烯化合物的方法包括：将干燥的青蒿干燥在C1-C4的低醇中浸渍24小时的步骤; 以及过滤，压缩和分馏的步骤。
-
公开(公告)号：KR1020090064708A
公开(公告)日：2009-06-22
申请号：KR1020070132006
申请日：2007-12-17
Applicant: 강화군
IPC: A61K31/045 , A61K36/282 , A61P35/00
Abstract: A pharmaceutical composition for containing an Artemisia herba extract for preventing and treating cancer is provided to obtain the effect of strong cytotoxicity to cells of ovarian cancer and leukemia. A pharmaceutical composition for preventing and treating cancer comprises a phytol as an active ingredient. The phytol is extracted from an Artemisia herba. The phytol is contained in a ratio of 0.01-97 weight% based on the total weight. The cancer is ovarian cancer and leukemia.
Abstract translation: 提供含有用于预防和治疗癌症的艾蒿提取物的药物组合物，以获得对卵巢癌和白血病细胞的强细胞毒性的作用。 用于预防和治疗癌症的药物组合物包括植醇作为活性成分。 从艾蒿提取植物醇。 植物醇的含量相对于总重量为0.01-97重量％。 癌症是卵巢癌和白血病。
-
公开(公告)号：KR1020070098092A
公开(公告)日：2007-10-05
申请号：KR1020060029316
申请日：2006-03-31
Applicant: 강화군
IPC: A61K36/282 , A61P3/10
Abstract: A composition for preventing and treating diabetes mellitus comprising the extract of gang-hwa mugwort(Artemisia) is provided to normalize sugar metabolism and lipid metabolism disorders caused by diabetes mellitus and activity of anti-oxidizing enzyme which is abnormally increased. A composition for preventing and treating diabetes mellitus comprises the extract of gang-hwa mugwort which is prepared by extracting gang-hwa mugwort with water or C1-C5 alcohol including methanol, ethanol, butanol, propanol and pentanol, wherein the diabetes mellitus is non-insulin dependent diabetes mellitus; and the composition is a pharmaceutical or food composition.
Abstract translation: 提供一种用于预防和治疗糖尿病的组合物，其包含由江蒿（艾蒿）提取物提供的糖代谢和由糖尿病引起的脂质代谢紊乱和异常升高的抗氧化酶的活性。 用于预防和治疗糖尿病的组合物包括通过用水或包括甲醇，乙醇，丁醇，丙醇和戊醇的C1-C5醇提取组合艾草而制备的组织提取物，其中糖尿病是非 - 胰岛素依赖性糖尿病; 并且组合物是药物或食物组合物。
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.03 seconds)
